Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

494

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

October 11, 2024

Study Completion Date

February 21, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

Ozempic®

The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.

DRUG

HDG1901

The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.

Trial Locations (1)

Unknown

Beijing Hospital, Beijing

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT06739044 - Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter